DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Novo - 1 Kerry Holford - 1 Holford - 1 Emily Field - 1 Maggie Fick - 1 Josephine Mason - 1 Alexandra Hudson - 1
Top related locs:
Danish United States
Top related orgs:
Soaring U.S - 1 Novo Nordisk's - 1 Nestle - 1 UBS - 1 Barclays - 1 May - 1 BMO Global Asset Management - 1 Alexandra Hudson Our - 1

Search resuls for: "BMO Global Asset Management"


2 mentions found


☆ Strong U.S. demand eases pressure on Novo to show weight-loss drug's health benefits
  + stars: | 2023-07-14 | by ( Maggie Fick | ) www.reuters.com   time to read: +3 min
Investors had been banking on the study results being the next big driver of the company's shares. That's due to high demand and after Novo raised its profit outlook in April, said Berenberg analyst Kerry Holford. If the risk reduction was between 10 and 14%, shares would decrease by less than 5%. A year ago, investors said a risk reduction of 10 to 14% in the trial would put significant downward pressure on the stock, Holford said. Barclays analyst Emily Field said a risk reduction as low as 11% could boost the stock.
Persons: Novo, Kerry Holford, Holford, Emily Field, Maggie Fick, Josephine Mason, Alexandra Hudson Organizations: Soaring U.S, Novo Nordisk's, Nestle, UBS, Reuters, Barclays, May, BMO Global Asset Management, Alexandra Hudson Our, Thomson Locations: Danish, United States
☆ Investors see big Novo Nordisk stock boost if obesity drug shows heart benefit
  + stars: | 2023-05-03 | by ( Maggie Fick | ) www.reuters.com   time to read: +5 min
Demand for the Danish company's weight-loss treatment Wegovy is soaring in the United States, leading it to significantly raise its full-year profit and sales expectations last month. "But most insurance companies (...) may need to see that data, to definitively see the correlation between weight loss and improved outcomes." Less than 15% could put downward pressure on the stock while around 10% would be a major disappointment, some of the investors and analysts said. Booming demand and production issues have caused shortages of Wegovy though, forcing Novo to delay launching the weekly injection in most of Europe. Even with the medical benefit, investors say the company faces a challenge convincing Europe's cost-conscious health authorities to pay for the drug.
0 next >>
Total: 2